Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Proxy Contest (May 2017)

44 slides from Rockwell Medical's proxy contest presentation, May 5, 2017

  1. Slide 1: The Case for Change at Rockwell Medical, Inc. (RMTI)

    THE CASE FOR CHANGE AT ROCKW!| ELL MEDICAL, INC. (RMTI)

  2. Slide 2: Disclaimer

    S) DISCLAIMER THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPEGIFIG INVESTMENT OBJECTIVE, FINANGIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVIC

  3. Slide 3: Table of Contents

    ®@ TABLE OF CONTENTS Executive Summary Why Are We Here? About Richmond Brothers and Mark H. Ravich Rockwell’s Track Record of Failure Rewarding Management Despite Underperformance The Rockwell Board — Not Looking out for ALL Shareholders Rockwell’s Response — Out of Touch and Defensive Our Impact

  4. Slide 4: Executive Summary

    ®@ EXECUTIVE SUMMARY 1. Richmond Brothers, Inc., together with Mark H. Ravich (collectively, “Richmond Brothers” or “we”), is the largest shareholder of Rockwell Medical, Inc. (“Rockwell,” “RMTI” or the “Company”), with ownership of approximately 11.8% of the Company’s outstanding shares — and has o

  5. Slide 5: The RMTI Opportunity

    THE RMTI OPPORTUNITY RMTI’s two most promising drugs are Calcitriol, a vitamin D drug, and Triferic, a revolutionary iron therapy. Under current management, these drugs have not been profitable and the Company has not experienced growth. We see the below as the value Mark H. Ravich can unlock if app

  6. Slide 6: Why Are We Here?

    ®@ WHY ARE WE HERE? ¢ Chronic underperformance — Rockwell’s strategy to bring promising drugs to market is not succeeding and has led to a dismal stock performance, resulting in value destruction for shareholders, particularly in reference to Triferic and Calcitriol. ¢ Poor communication and lack of

  7. Slide 7: Why Are We Here? Repeated efforts to engage

    7, S@) WHY ARE WE HERE? We have made repeated efforts to engage constructively with Rockwell Members of Richmond Brothers entered David Richmond, Mark Ravich, and other shareholders David Richmond into a Group Agreement and agreed to corresponded with Rockwell, sending letters and individually sent

  8. Slide 8: Positive Market Reaction to Richmond Brothers Filing

    ® POSITIVE MARKET REACTION TO RICHMOND BROTHERS FILING RMTI Share Price Shareholders clearly want change. “Calculated as of May {2017 2/21/17 — Richmond Brothers / Ravich 13D filing Source: Yahoo! Finance, EDGAR g

  9. Slide 9: Richmond Brothers and Mark H. Ravich

    ®@ RICHMOND BROTHERS AND MARK H. RAVICH Richmond Brothers, Inc. * Michigan-based SEC registered investment advisor and wealth management firm ¢ Founded in 1994 * — RMTlis Richmond Brothers’ first activist situation; activism is not a standard component of its investment strategy Mark H. Ravich . Pri

  10. Slide 10: Rockwell's Series of Failures

    (®) ROCKWELL’S SERIES OF FAILURES

  11. Slide 11: Sustained Underperformance

    @ SUSTAINED UNDERPERFORMANCE RMTI’s history is characterized by disappointing performance and lack of successful execution * Share price is down 52.5% over the past 3 years’ * RMTI underperformed the NASDAQ Biotechnology Index (NBI) by 315% over the past 10 years * RMTI is being sued by Baxter Healt

  12. Slide 12: Sustained Underperformance: 1, 3, 5, and 10 Year

    —, ® SUSTAINED UNDERPERFORMANGE: I, 3, 5, AND 10 YEAR RMTI’s history is characterized by disappointing performance and lack of successful execution 1-Year 3-Year §(5-Year 10-Year RMTI -24.2% -52.5% | -38.6% -21.8% NBI Index 12.5% 12.4% 151.2% 293.2% RMTI -36.7% -64.9% |-189.8% | -315% Underperforman

  13. Slide 13: Consistent Value Destruction

    & CONSISTENT VALUE DESTRUCTION Total Shareholder Return - 5 Years 30% 1116 BofA/Merrill downgrad: a to erpe rt re 3/16 Stifel RMTI to underperform from neutral 0% downgrades RMTI to hold from buy 00% 1/16 BTIG drops verage of RMTI 1505 3/17 Stifel drops 100% coverage of RMTI 8/14 Calcitriol 115 Trif

  14. Slide 14: Triferic — Failure to Monetize

    @) TRIFERIC — FAILURE TO MONETIZE * It has now been over two years since the approval of Triferic, Rockwell's promising drug that has the potential to become the standard of care iron maintenance therapy for hemodialysis patients — and the drug has not generated material revenue. + After leading ana

  15. Slide 15: Triferic's High Potential

    ®@ TRIFERIC’S HIGH POTENTIAL... Analysts have recognized the clear potential of Triferic “On a longer term basis, if Triferic advances towards a full commercial launch, we believe that revenue can exceed $300 million given the expected ramp in Triferic and Calcitriol. Applying a 7x revenue multiple

  16. Slide 16: Hindered by Poor Execution

    Ze » HINDERED BY POOR @ EXECUTION... Analysts have also called Rockwell’s failure to move it forward “Likelihood and timing of transitional add-on payment decision for Triferic remains oapaque...In the absence of any tangible update, we have removed 2017 revenues for Triferic from our model.” — Marc

  17. Slide 17: Has Left Many with Unanswered Questions

    — ) .. HAS LEFT MANY WITH UNANSWERED QUESTIONS “If | heard you correctly, you're not really going to be launching Triferic until you get approval of this powder, this new packaging, and it doesn't seem like you have any kind of agreement on reimbursement from CMS...so are you also not going to able

  18. Slide 18: Calcitriol — Failure to Monetize

    @) CALCITRIOL — FAILURE TO MONETIZE Calcitriol, the Company’s vitamin D drug, has been approved for nearly three years but still is not on the market. >» March 2013: Rockwell says that Calcitriol will be submitted later that month under expedited review, and that it should launch immediately upon ap

  19. Slide 19: Management's Failure to Launch — In Their Own Words

    @) MANAGEMENT'S FAILURE TO LAUNCH — IN THEIR OWN WORDS call Broken Promise “On our previous call, we stated that, based on our prelaunch activity at that time, our commercial launch for Triferic and Calcitriol was estimated for the July-August timeframe. As of today, August 4, I'm happy to teil you

  20. Slide 20: Leadership Is Clearly Out of Touch with Shareholders

    ® LEADERSHIP IS CLEARLY OUT OF TOUCH WITH SHAREHOLDERS In an April 2015 interview with Prosper, Mi. Chicini Boassed of It’s been more than two years since Mr. Chioini’s "We don't feel like interview—and real we've won the progress and championship yet. monetization remains undelivered. We're in the

  21. Slide 21: Failure to Communicate with the Market and Shareholders

    — ® FAILURE TO COMMUNICATE WITH THE MARKET AND SHAREHOLDERS RMT! stands out among its competitors as a company unwilling to engage in constructive discussion with shareholders and the analyst community. Company Current Number of Allow Shareholder Sell-Side Analysts Questions on Earnings Calls? RMTI

  22. Slide 22: Rewarding Management Despite Underperformance

    REWARDING MANAGEMENT (@) DESPITE UNDERPERFORMANCE

  23. Slide 23: Management Is Overcompensated

    ® MANAGEMENT IS OVERCOMPENSATED Rockwell’s historical compensation practices reinforce the incumbent Board’s obvious disinterest in proactively taking action in the best interests of shareholders. « Chairman and CEO Rob Chicini’s pay was 5.49 times the median of the Company’s peers in 2014 and 4.61

  24. Slide 24: Rob Chioini's Stock Options

    @ ROB CHIOINI'S STOCK OPTIONS While public shareholders were significantly diluted by the Company’s “botched” financing in 2013 (where the Company allowed itself to run so low on funds that short sellers were able to run a classic liquidity squeeze short on the Company), Rob Chioini has managed to m

  25. Slide 25: Rob Chioini's Bonus

    @ Ros CHIOINI’s BONUS Why did Rob get a $805,205 (95% out of 100% of pay potential) bonus in 2016 for accomplishing basically nothing? * Failed to get Triferic pricing approved during the Obama administration despite repeatedly assuring shareholders he would. * Failed to launch Calcitriol once again

  26. Slide 26: Shareholders Are Clearly Frustrated

    @) SHAREHOLDERS ARE CLEARLY FRUSTRATED Rockwell shareholders voted down the Company’s proposed executive compensation plan (LTIP) at the 2016 Annual Meeting. Nearly 11 million “withhold” votes were cast for the director running for election in 2016. Ttem 5.07 Submission of Mattcrs to a Vote of Secur

  27. Slide 27: The Board Appears Tone-Deaf to Shareholder Concerns

    @ THE BOARD APPEARS TONE-DEAF TO SHAREHOLDER CONCERNS Recently, Rockwell stooped to new lows with its proposed 2017 equity compensation plan. * Itis shocking that the Board believed introducing a significantly more dilutive plan was appropriate after shareholders voted down the 2016 plan, which soug

  28. Slide 28: Rockwell Only Reactively Pared Back 2017 Equity Compensation Plan

    @ ROCKWELL ONLY REACTIVELY PARED BACK 2017 EQUITY COMPENSATION PLAN Rockwell only revised its 2017 equity compensation pian to remove the “evergreen” provision after we publicly criticized it in an April 6 press release. + While the removal of the “evergreen” provision is a victory for shareholders,

  29. Slide 29: Performance Standards More for Show Than Hurdle

    —. ® ROCKWELL’S PERFORMANCE STANDARDS APPEAR TO BE MORE FOR SHOW THAN AN ACTUAL HURDLE The performance tests for 2017 equity grants all but assure the vesting of awards over time. Additionally, only ONE test must be met to fully vest the award. * Test 1: Reported net sales in any four consecutive qu

  30. Slide 30: Why Should Management Be Rewarded for Poor Performance?

    ® WHY SHOULD MANAGEMENT BE REWARDED FOR POOR PERFORMANCE? It Doesn’t Add Up Despite the Company losing half its value in three years, Chairman and CEO Rob Chioini has remained excessively compensated—by industry standards and compared to peers. Performance is calculated irom 2/20/14 — 2/20/17 Source

  31. Slide 31: Rockwell's Troubling Corporate Governance Practices

    ROCKWELL S TROUBLING CORPORATE GOVERNANCE @) PRACTICES

  32. Slide 32: Rockwell's Litany of Governance Flaws

    ROCKWELL’S LITANY OF GOVERNANCE FLAWS X Entrenched Board — Of the Company’s five current directors, three have been on the Board for 17 years and a fourth has been a member for more than 11 years.' Despite adding Dr. Robin Smith to the Board in June 2016, Rockwell didn’t allow its shareholders to vo

  33. Slide 33: Dr. Robin Smith — Not What Rockwell Needs

    @ Dr. ROBIN SMITH — NOT WHAT ROCKWELL NEEDS Rockwell praised Smith’s “strategic, operational and management experience”, but let’s look at the facts around her previous leadership and board experience: X Smith is the former CEO of the NeoStem family of companies (re-named Caladrius Biosciences, Inc.

  34. Slide 34: David Domzalski — Not What Rockwell Needs

    @ David DomZaLskI— NOT WHAT ROCKWELL NEEDS Rockwell has touted Domzalski’s experience, but let’s look at the facts: * Until 2014, Domzalski’s experience was only in Sales and Marketing. With 85% of RMTI customers controlled by 7 companies, all of which are known to RMTI because of their dialysate bu

  35. Slide 35: Stale and Interconnected Board

    @ STALE AND INTERCONNECTED BOARD Rob L. Chioini, Chairman and CEO Board tenure: 17 years Boyd and Holt are both Co-Owners and Managing Partners of Southeast Acute Services, LLC and Southern Renal Administrators Kenneth L. Holt” Ronald D. Boyd Board tenure: 17 years Board tenure: 17 years 7 Patrick J

  36. Slide 36: Rockwell's Response — Out of Touch and Purely Defensive

    ROCKWELL’S RESPONSE — OUT OF TOUCH AND PURELY DEFENSIVE

  37. Slide 37: Corporate Governance "Enhancements"

    y ) CORPORATE GOVERNANCE “ENHANCEMENTS ’? * Rockwell’s recently announced corporate governance “enhancements” are too little, too late. We believe they are “window dressing” put in place in an effort to win the proxy contest. o The last conference call, which occurred after our involvement, was the

  38. Slide 38: Rockwell's Idea of Communication Is Suing Shareholders

    — SHAREHOLDERS LNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ROCKWELL MEDICAL, INC., Plaintiff. Case No. 17-cv-10757 vs. Hon. RICHMOND BROTHERS, INC., a Michigan corporation, RBI PRIVATE INV! LLC, a Delaware limited liability company, RBI PI MANAGER, LLC, a Delaware limited liabi

  39. Slide 39: The Change Rockwell Needs

    @; THE CHANGE ROCKWELL NEEDS

  40. Slide 40: Mark H. Ravich will ask the right questions

    Mark H. Ravich will ask the right questions, hold management accountable and push back against pay for non-performance

  41. Slide 41: Mark H. Ravich — Strong Board and Executive Experience

    @ MARK H. RAVICH — STRONG BOARD AND EXECUTIVE EXPERIENCE Mr. Ravich’s prior board experience coupled with his financial and management expertise will make him a valuable addition to the Board. Mark H. Ravich Lo \ Management Experience MR INSTRUMENTS INCORPORATED a Lo”. Board —+Dilon Experience = [-~

  42. Slide 42: Our Impact — Aligned with All Shareholders

    VN OUR IMPACT — ALIGNED WITH ALL SHAREHOLDERS Below are potential steps that Mark would take to improve Rockwell from corporate governance and strategic standpoints + Hire an outside consutant or self review the Board to determine successes and pain points and 10 develop best practices + Appoint a l

  43. Slide 43: Appendix

    (®) APPENDIX

  44. Slide 44: Mark H. Ravich — Biography

    @ Mark H. RAVICH — BIOGRAPHY Mark H. Ravich, age 64, currently serves as President of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. Mr. Ravich has also served as a director of Orchids Paper Products Company (NYSEMKT:TIS), a nationa

Rockwell Medical — Proxy Contest (May 2017) on 6ix